[Radiotherapy and targeted therapy/immunotherapy].

Date publication

octobre 2016

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine

Tous les auteurs :
Antoni D, Bockel S, Deutsch E, Mornex F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27614521

Résumé

Thanks to recent advances achieved in oncologic systemic and local ablative treatment, the treatments become more and more efficient in term of local control and overall survival. Thus, the targeted therapies, immunotherapy or stereotactic radiotherapy have modified the management of patients, especially in case of oligometastatic disease. Many questions are raised by these innovations, particularly the diagnosis and management of new side effects or that of the combination of these different treatments, depending on the type of primary tumor. Fundamental data are available, while clinical data are still limited. Ongoing trials should help to clarify the clinical management protocols. This manuscript is a review of the combination of radiotherapy and targeted therapy/immunotherapy.

Mots clés

Angiogenesis Inhibitors, therapeutic use, Humans, Immunotherapy, Neoplasms, immunology, Protein Kinase Inhibitors, therapeutic use, Proto-Oncogene Proteins B-raf, antagonists & inhibitors, Radiotherapy, Adjuvant, Receptor Protein-Tyrosine Kinases, antagonists & inhibitors, Receptor, Epidermal Growth Factor, antagonists & inhibitors

Référence

Cancer Radiother. 2016 Oct;20(6-7):434-41